DOCSLIB.ORG

Preclinical Discovery of Ixabepilone, a Highly Active Antineoplastic Agent

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Preclinical Discovery of Ixabepilone, a Highly Active Antineoplastic Agent View metadata, citation and similar papers at core.ac.uk brought to you by CORE provided by Springer - Publisher Connector Cancer Chemother Pharmacol (2008) 63:157–166 DOI 10.1007/s00280-008-0724-8 ORIGINAL ARTICLE Preclinical discovery of ixabepilone, a highly active antineoplastic agent Francis Y. F. Lee · Robert Borzilleri · Craig R. Fairchild · Amrita Kamath · Richard Smykla · Robert Kramer · Gregory Vite Received: 30 November 2007 / Accepted: 26 February 2008 / Published online: 18 March 2008 © Springer-Verlag 2008 Abstract The epothilones and their analogs constitute a These favorable preclinical characteristics have since novel class of antineoplastic agents, produced by the myxo- translated to the clinic. Ixabepilone has shown promising bacterium Sorangium cellulosum. These antimicrotubule phase II clinical eYcacy and acceptable tolerability in a agents act in a similar manner to taxanes, stabilizing micro- wide range of cancers, including heavily pretreated and tubules and resulting in arrested tumor cell division and drug-resistant tumors. Based on these results, a randomized apoptosis. Unlike taxanes, however, epothilones and their phase III trial was conducted in anthracycline-pretreated or analogs are macrolide antibiotics, with a distinct tubulin resistant and taxane-resistant metastatic breast cancer to binding mode and reduced susceptibility to a range of com- evaluate ixabepilone in combination with capecitabine. mon tumor resistance mechanisms that limit the eVective- Ixabepilone combination therapy showed signiWcantly supe- ness of taxanes and anthracyclines. While natural rior progression-free survival and tumor responses over epothilones A and B show potent antineoplastic activity in capecitabine alone. vitro, these eVects were not seen in preclinical in vivo mod- els due to their poor metabolic stability and unfavorable Keywords Antimicrotubule · III-Tubulin · Epothilone · pharmacokinetics. A range of epothilone analogs was syn- Multidrug resistance · Preclinical thesized, therefore, with the aim of identifying those with more favorable characteristics. Here, we describe the pre- clinical characterization and selection of ixabepilone, a Introduction semi-synthetic epothilone B analog, among many other epothilone analogs. Ixabepilone demonstrated superior pre- Since the clinical antitumor activity of the taxanes was dis- clinical characteristics, including high metabolic stability, covered in the 1990s, the rationale for using microtubule- low plasma protein binding and low susceptibility to multi- stabilizing agents in the treatment of cancer is undisputed drug resistance protein-mediated eZux, all of which were [1]. Taxanes are clinically active against a wide range of predictive of potent in vivo cell-killing activity. Ixabepilone tumor types, and play a key role in the treatment of both also demonstrated in vivo antitumor activity in a range of primary and metastatic breast cancer [2]. However, resis- human tumor models, several of which displayed resistance tance to cytotoxic drugs (including taxanes) is common, to commonly used agents such as anthracyclines and taxanes. and results in reduced response rates and ultimate disease progression in most patients with metastatic cancer [3]. While some tumors display intrinsic resistance to chemo- F. Y. F. Lee · R. Borzilleri · C. R. Fairchild · A. Kamath · therapeutic drugs, and thus show no response, others are R. Smykla · R. Kramer · G. Vite Bristol-Myers Squibb Pharmaceutical Research Institute, initially responsive to chemotherapy, but subsequently Princeton, NJ, USA develop acquired resistance. Both intrinsic and acquired resistance lead to a requirement for alternative treatment F. Y. F. Lee (&) options [3]. Bristol-Myers Squibb Co., P.O. Box 4000, K22-03, Princeton, NJ, USA A major mechanism by which tumors display resistance e-mail: [email protected] to commonly used agents such as taxanes and anthracyclines 123 158 Cancer Chemother Pharmacol (2008) 63:157–166 is through overexpression of multidrug resistance (MDR) development and selection of a particular epothilone proteins including P-glycoprotein (P-gp) and multidrug analog, BMS-247550 (ixabepilone), a semi-synthetic analog resistance-associated protein (MRP)-1 [4]. Overexpression of natural epothilone B that has shown phase II clinical activ- of these eZux pump proteins causes retention of sub-thera- ity in a wide range of tumor types, including those heavily peutic concentrations of drug in tumor cells, which results pretreated with, and/or resistant to, prior therapies [16–26]. in a lack of eYcacy. In some tumors that are intrinsically resistant to chemotherapy, expression of MDR proteins reXects the constitutive expression of these proteins by the Epothilones and their analogs: a novel class tissues from which the tumors are derived (for example, of antineoplastic agents liver and kidney). However, in tumors derived from tissue types that do not express MDR proteins physiologically, Epothilones are 16-member macrolides with unique anti- treatment with chemotherapy can induce expression of bacterial and antifungal activity. Preclinical experiments these proteins. This results in acquired resistance to the have shown that natural epothilones A and B have potent chemotherapy agent used, in addition to drugs of the same antineoplastic activity against a wide range of tumor cell class and, on occasion, of diVerent classes [3]. In the case lines in vitro [14, 27]. This is particularly true for epothi- of the taxanes, at least one other mechanism of drug resis- lone B, which showed greater in vitro activity when com- tance is known to exist: the overexpression of the III-tubu- pared with epothilone A [28, 29]. However, this promising lin isoform in preference to the II isoform reduces the in vitro activity of these natural epothilones did not trans- eYcacy of taxanes, as these drugs speciWcally target the II late into robust in vivo preclinical antitumor eYcacy [30]. isoform [5–8]. This was due to the poor metabolic stability and unfavor- In recent years, there has been a great deal of interest able pharmacokinetic properties of natural epothilones seen among the oncology community in targeted agents. It is in rodent models. Synthetic and semi-synthetic epothilone now widely acknowledged that agents such as trastuzumab analogs were, therefore, developed, with the aim of yield- (which targets HER2 in breast cancer) and bevacizumab ing more favorable preclinical characteristics that would (which targets VEGF to inhibit angiogenesis in a range of lead to improved in vivo activity [31, 32]. This was possi- solid tumors) have the potential beneWts of at least compa- ble due to the fact that epothilones have a structure of only rable eYcacy and reduced side-eVects compared with cyto- moderate complexity, and are amenable to total and semi- toxic agents. However, targeted therapies are only eVective synthesis. A range of semisynthetic analogs was developed in subsets of patients with tumors expressing the target and tested by Bristol–Myers Squibb in order to identify molecule, hence it is likely that cytotoxic agents will candidates with a superior eYcacy and safety proWle versus remain important in the treatment of cancer, either in com- epothilone B. Of these, ixabepilone is an analog rationally bination with other agents [as seen clinically with paclitaxel designed for high in vivo eYcacy, good metabolic stability, in combination with bevacizumab in trials of non-small cell low protein binding and increased water solubility. The lac- lung carcinoma (NSCLC)] or second-line to other therapies tone oxygen is replaced with nitrogen, resulting in the lac- [9, 10]. There is, therefore, a pressing need for the develop- tam compound (Fig. 1b). SigniWcantly, this lactam ring is ment of novel antineoplastic agents that are able to over- not susceptible to hydrolysis by esterases, conferring meta- come major mechanisms of tumor drug resistance. bolic stability on ixabepilone. Because of its improved Natural epothilones and their analogs are a novel class of water solubility, ixabepilone has a reduced requirement in antineoplastic agents, produced by the myxobacterium its formulation for the solubilizing agent cremophor, an Sorangium cellulosum [11, 12]. Like the taxanes, epothil- agent that has been associated with hypersensitivity ones promote tumor cell death by stabilizing microtubules reaction in patients. and inducing apoptosis [13]. However, as macrolide antibi- otics, the epothilones are structurally unrelated to taxanes and have a distinct tubulin-binding mode. Moreover, unlike Preclinical evaluation of ixabepilone taxanes and anthracyclines, epothilones have low suscepti- bility to multiple mechanisms of tumor cell resistance, In order to be of clinical value, an epothilone analog must: including MDR, III-tubulin overexpression and -tubulin (1) be eYcacious, resulting in clinically meaningful mutations [8, 14, 15]. responses at practical concentrations; (2) have an accept- The potential for reduced susceptibility to common able safety proWle; and (3) be readily available through mechanisms of tumor resistance led to preclinical and scalable synthesis. clinical evaluation of natural epothilones A–F (Fig. 1a), While the in vitro cytotoxicity/activity of the drug may and a wide range of synthetic and semi-synthetic analogs of give some indication of how potent the drug will be in vivo, these agents. This review will describe the preclinical this is not always the case (as seen for natural epothilones
Load more

Recommended publications
  • First Genomic Insights Into Members of a Candidate Bacterial Phylum Responsible for Wastewater Bulking
    First genomic insights into members of a candidate bacterial phylum responsible for wastewater bulking Yuji Sekiguchi1, Akiko Ohashi1, Donovan H. Parks2, Toshihiro Yamauchi3, Gene W. Tyson2,4 and Philip Hugenholtz2,5 1 Biomedical Research Institute, National Institute of Advanced Industrial Science and Technology (AIST), Tsukuba, Ibaraki, Japan 2 Australian Centre for Ecogenomics, School of Chemistry and Molecular Biosciences, The University of Queensland, St. Lucia, Queensland, Australia 3 Administrative Management Department, Kubota Kasui Corporation, Minato-ku, Tokyo, Japan 4 Advanced Water Management Centre, The University of Queensland, St. Lucia, Queensland, Australia 5 Institute for Molecular Bioscience, The University of Queensland, St. Lucia, Queensland, Australia ABSTRACT Filamentous cells belonging to the candidate bacterial phylum KSB3 were previously identified as the causative agent of fatal filament overgrowth (bulking) in a high-rate industrial anaerobic wastewater treatment bioreactor. Here, we obtained near complete genomes from two KSB3 populations in the bioreactor, including the dominant bulking filament, using diVerential coverage binning of metagenomic data. Fluorescence in situ hybridization with 16S rRNA-targeted probes specific for the two populations confirmed that both are filamentous organisms. Genome-based metabolic reconstruction and microscopic observation of the KSB3 filaments in the presence of sugar gradients indicate that both filament types are Gram-negative, strictly anaerobic fermenters capable of
    [Show full text]
  • Studies Towards Secondary Metabolite Formation in Myxobacteria: Elucidation of Biosynthetic Pathways and Yield Optimization
    Studies towards secondary metabolite formation in Myxobacteria: Elucidation of biosynthetic pathways and yield optimization Dissertation zur Erlangung des Grades des Doktors der Naturwissenschaften der Naturwissenschaftlich-Technischen Fakultät III Chemie, Pharmazie, Bio- und Werkstoffwissenschaften der Universität des Saarlandes von Stefan Müller Saarbrücken 2015 Tag des Kolloquiums: 31.07.2015 Dekan: Prof. Dr. Dirk Bähre Berichterstatter: Prof. Dr. Rolf Müller Prof. Dr. Rolf W. Hartmann Vorsitz: Prof. Dr. Uli Kazmaier Akad. Mitarbeiter: Dr. Judith Becker Diese Arbeit entstand unter der Anleitung von Prof. Dr. Rolf Müller in der Fachrichtung 8.2 Pharmazeutische Biotechnologie der Naturwissenschaftlich-Technischen Fakultät III der Universität des Saarlandes in der Zeit von Mai 2011 bis April 2015. Veröffentlichungen der Dissertation Veröffentlichungen der Dissertation Teile dieser Arbeit wurden vorab mit Genehmigung der Naturwissenschaftlich-Technischen Fakultät III, vertreten durch den Mentor der Arbeit, in folgenden Beiträgen veröffentlicht: Müller S, Rachid S, Hoffmann T, Surup F, Volz C, Zaburannyi N, & Müller R (2014) Biosynthesis of crocacin involves an unusual hydrolytic release domain showing similarity to condensation domains. Chemistry & Biology, 21 (7), 855-865. Hoffmann T, Müller S, Nadmid S, Garcia R, & Müller R (2013) Microsclerodermins from terrestrial myxobacteria: An intriguing biosynthesis likely connected to a sponge symbiont. Journal of the American Chemical Society, 135 (45), 16904-16911. Darüber hinaus konnte zu einer weiteren Publikation, welche nicht Teil dieser Arbeit ist, beigetragen werden: Jahns C, Hoffmann T, Müller S, Gerth K, Washausen P, Höfle G, Reichenbach H, Kalesse M, & Müller R (2012) Pellasoren: Structure elucidation, biosynthesis, and total synthesis of a cytotoxic secondary metabolite from Sorangium cellulosum. Angewandte Chemie International Edition, 51 (21), 5239-5243.
    [Show full text]
  • IXEMPRA Label
    HIGHLIGHTS OF PRESCRIBING INFORMATION ----------------------------CONTRAINDICATIONS------------------------------- These highlights do not include all the information needed to use ® ® • Hypersensitivity to drugs formulated with Cremophor EL (4). IXEMPRA safely and effectively. See full prescribing information for • Baseline neutrophil count <1500 cells/mm3 or a platelet count ® <100,000 cells/mm3 (4). IXEMPRA . • Patients with AST or ALT >2.5 x ULN or bilirubin >1 x ULN must not be treated with IXEMPRA in combination with capecitabine (4). ® IXEMPRA Kit (ixabepilone) for Injection, for intravenous infusion only ------------------------WARNINGS AND PRECAUTIONS----------------------- Initial U.S. Approval: 2007 • Peripheral Neuropathy: Monitor for symptoms of neuropathy, primarily sensory. Neuropathy is cumulative, generally reversible and should be WARNING: TOXICITY IN HEPATIC IMPAIRMENT managed by dose adjustment and delays (2.2, 5.1). See full prescribing information for complete boxed warning. • Myelosuppression: Primarily neutropenia. Monitor with peripheral blood ® IXEMPRA in combination with capecitabine must not be given to cell counts and adjust dose as appropriate (2.2, 5.2). patients with AST or ALT >2.5 x ULN or bilirubin >1 x ULN due to • Hypersensitivity reaction: Must premedicate all patients with an H1 increased risk of toxicity and neutropenia-related death. (4, 5.3) antagonist and an H2 antagonist before treatment (2.3, 5.4). • Fetal harm can occur when administered to a pregnant woman. Women ---------------------------RECENT
    [Show full text]
  • Correlation Between Sorangium Cellulosum Subgroups and Their Potential for Secondary Metabolite Production
    J. Microbiol. Biotechnol. (2013), 23(3), 297–303 http://dx.doi.org/10.4014/jmb.1210.10054 First published online January 22, 2013 pISSN 1017-7825 eISSN 1738-8872 Correlation Between Sorangium cellulosum Subgroups and Their Potential for Secondary Metabolite Production Lee, Chayul, Dongju An, Hanbit Lee, and Kyungyun Cho* Myxobacteria Bank, Department of Biotechnology, Hoseo University, Asan 336-795, Korea Received: October 18, 2012 / Revised: November 15, 2012 / Accepted: November 16, 2012 Phylogenetic analysis of the groEL1 and xynB1 gene worldwide [4]; approximately 1,000 of these strains have sequences from Sorangium cellulosum strains isolated in been isolated in Korea [5]. Secondary metabolites produced Korea previously revealed the existence of at least 5 by S. cellulosum were initially isolated from different subgroups (A-E). In the present study, we used sequence strains. However, the number of strains known to produce analysis of polymerase chain reaction-amplified biosynthetic identical metabolites has increased, as the isolated strains genes of strains from the 5 subgroups to indicate correlations have been characterized [7, 14]. The relationships between between S. cellulosum subgroups and their secondary strains producing the same metabolites remain to be metabolic gene categories. We detected putative biosynthetic elucidated. We previously reported that S. cellulosum genes for disorazol, epothilone, ambruticin, and soraphen strains isolated in Korea could be classified into 5 in group A, group C, group D, and group E strains, subgroups based on the DNA sequences of their groEL1 respectively. With the exception of KYC3204, culture and xynB1 genes, which code for heat-shock protein and extracts from group A, group B, and group C strains cellulase, respectively [15].
    [Show full text]
  • Extraordinary Expansion of a Sorangium Cellulosum Genome
    OPEN Extraordinary expansion of a Sorangium SUBJECT AREAS: cellulosum genome from an alkaline ENVIRONMENTAL MICROBIOLOGY milieu BACTERIA Kui Han1, Zhi-feng Li1, Ran Peng1, Li-ping Zhu1, Tao Zhou2, Lu-guang Wang1, Shu-guang Li1, MICROBIAL GENETICS Xiao-bo Zhang2, Wei Hu1, Zhi-hong Wu1, Nan Qin2 & Yue-zhong Li1 MICROBIAL ECOLOGY 1State Key Laboratory of Microbial Technology, School of Life Science, Shandong University, Jinan 250100, China, 2Beijing Received Genomics Institute, Shenzhen, 518083, China. 4 March 2013 Accepted Complex environmental conditions can significantly affect bacterial genome size by unknown mechanisms. 13 June 2013 The So0157-2 strain of Sorangium cellulosum is an alkaline-adaptive epothilone producer that grows across Published a wide pH range. Here, we show that the genome of this strain is 14,782,125 base pairs, 1.75-megabases larger than the largest bacterial genome from S. cellulosum reported previously. The total 11,599 coding 1 July 2013 sequences (CDSs) include massive duplications and horizontally transferred genes, regulated by lots of protein kinases, sigma factors and related transcriptional regulation co-factors, providing the So0157-2 strain abundant resources and flexibility for ecological adaptation. The comparative transcriptomics Correspondence and approach, which detected 90.7% of the total CDSs, not only demonstrates complex expression patterns requests for materials under varying environmental conditions but also suggests an alkaline-improved pathway of the insertion and duplication, which has been genetically testified, in this strain. These results provide insights into and a should be addressed to paradigm for how environmental conditions can affect bacterial genome expansion. Y.-Z.L. ([email protected].
    [Show full text]
  • Current Trends in Myxobacteria Research
    Ann Microbiol (2016) 66:17–33 DOI 10.1007/s13213-015-1104-3 REVIEW ARTICLE Current trends in myxobacteria research Wioletta Wrótniak-Drzewiecka1 & Anna Joanna Brzezińska1 & Hanna Dahm1 & Avinash P. Ingle 2 & Mahendra Rai 2 Received: 5 March 2015 /Accepted: 19 May 2015 /Published online: 12 June 2015 # Springer-Verlag Berlin Heidelberg and the University of Milan 2015 Abstract Myxobacteria are fascinating Gram-negative bacte- Keywords Myxobacteria . Ecology . Cytology . Enzymatic ria whose life cycle includes the formation of multicellular activity . Secondary metabolism . Social interactions fruiting bodies that contain about 100,000 cells differentiated as asexual spores for their long-term survival. They move by gliding on surfaces, an activity that helps them carry out their Introduction primitive kind of multicellular development. Myxobacteria have multiple traits that are clearly social in nature; they move Myxobacteria (slime bacteria) are rod-shaped Gram-negative and feed socially. These processes require specific intercellu- bacteria that move by gliding. They typically travel in swarms, lar signals, thereby exhibiting a sophisticated level of the inter- containing many cells kept together by intercellular molecular organismal communication. Myxobacteria are predators. signals. Bacterial gliding is a process whereby a bacterium can Predation is social not only with respect to searching for prey move under its own power. For many bacteria, the mechanism (motility) but also in the killing of prey. Swarming groups of of gliding is unknown or only partially known, and different cells secrete antibiotics and bacteriolytic compounds that kill bacteria (cyanobacteria, cytophaga-flavobacteria) have dis- and lyse their prey, and food is thereby released. Since the last tinct mechanisms of movement.
    [Show full text]
  • Maxbin: an Automated Binning Method to Recover Individual
    Wu et al. Microbiome 2014, 2:26 http://www.microbiomejournal.com/content/2/1/26 METHODOLOGY Open Access MaxBin: an automated binning method to recover individual genomes from metagenomes using an expectation-maximization algorithm Yu-Wei Wu1,2*, Yung-Hsu Tang1,3, Susannah G Tringe4,5, Blake A Simmons1,6 and Steven W Singer1,7 Abstract Background: Recovering individual genomes from metagenomic datasets allows access to uncultivated microbial populations that may have important roles in natural and engineered ecosystems. Understanding the roles of these uncultivated populations has broad application in ecology, evolution, biotechnology and medicine. Accurate binning of assembled metagenomic sequences is an essential step in recovering the genomes and understanding microbial functions. Results: We have developed a binning algorithm, MaxBin, which automates the binning of assembled metagenomic scaffolds using an expectation-maximization algorithm after the assembly of metagenomic sequencing reads. Binning of simulated metagenomic datasets demonstrated that MaxBin had high levels of accuracy in binning microbial genomes. MaxBin was used to recover genomes from metagenomic data obtained through the Human Microbiome Project, which demonstrated its ability to recover genomes from real metagenomic datasets with variable sequencing coverages. Application of MaxBin to metagenomes obtained from microbial consortia adapted to grow on cellulose allowed genomic analysis of new, uncultivated, cellulolytic bacterial populations, including an abundant myxobacterial population distantly related to Sorangium cellulosum that possessed a much smaller genome (5 MB versus 13 to 14 MB) but has a more extensive set of genes for biomass deconstruction. For the cellulolytic consortia, the MaxBin results were compared to binning using emergent self-organizing maps (ESOMs) and differential coverage binning, demonstrating that it performed comparably to these methods but had distinct advantages in automation, resolution of related genomes and sensitivity.
    [Show full text]
  • Insights from 20 Years of Bacterial Genome Sequencing
    Funct Integr Genomics DOI 10.1007/s10142-015-0433-4 REVIEW Insights from 20 years of bacterial genome sequencing Miriam Land & Loren Hauser & Se-Ran Jun & Intawat Nookaew & Michael R. Leuze & Tae-Hyuk Ahn & Tatiana Karpinets & Ole Lund & Guruprased Kora & Trudy Wassenaar & Suresh Poudel & David W. Ussery Received: 19 January 2015 /Revised: 11 February 2015 /Accepted: 12 February 2015 # The Author(s) 2015. This article is published with open access at Springerlink.com Abstract Since the first two complete bacterial genome se- in a few hours and identify some types of methylation sites quences were published in 1995, the science of bacteria has along the genome as well. Sequencing of bacterial genome dramatically changed. Using third-generation DNA sequenc- sequences is now a standard procedure, and the information ing, it is possible to completely sequence a bacterial genome from tens of thousands of bacterial genomes has had a major impact on our views of the bacterial world. In this review, we This manuscript has been authored by a contractor of the US Government explore a series of questions to highlight some insights that under contract No. DE-AC05-00OR22725. Accordingly, the US comparative genomics has produced. To date, there are ge- Government retains a paid-up, nonexclusive, irrevocable, worldwide license to publish or reproduce the published form of this contribution, nome sequences available from 50 different bacterial phyla prepare derivative works, distribute copies to the public, and perform and 11 different archaeal phyla. However, the distribution is publicly and display publicly or allow others to do so, for US quite skewed towards a few phyla that contain model organ- Government purposes.
    [Show full text]
  • Morphologies and Phylogenetic Classification of Cellulolytic Myxobacteria
    http://www.paper.edu.cn System. Appl. Microbiol. 26, 104–109 (2003) © Urban & Fischer Verlag http://www.urbanfischer.de/journals/sam Morphologies and Phylogenetic Classification of Cellulolytic Myxobacteria Zhang-Cai Yan, Bing Wang, Yue-Zhong Li, Xun Gong, Huai-Qiang Zhang, and Pei-Ji Gao State Key Laboratory of Microbial Technology, College of Life Science, Shandong University, Jinan, China Received: September 15, 2002 Summary The evolutionary distances of the 16S rDNA sequences in cellulolytic myxobacteria are less than 3%, which units all the strains into a single genus, Sorangium. The size of myxospores and the shape of spo- rangioles, rather than fruiting body colors or swarm morphologies are consistent with the changes of the 16S rDNA sequences. It is suggested that there are at least two species in the genus Sorangium: one in- cludes strains with small myxospores and spherical sporangioles, and the color of the fruiting bodies is normally orange or brown, though sometimes yellow or black. The second species has large myxospores, polyhedral sporangioles with many inter-cystic substrates, and normally deep brown to black color. Key words: cellulolytic – myxobacteria – Sorangium – morphologies – 16S rDNA – Classification Introduction Myxobacteria are unique among bacteria for their lulosum, but suggested that there were at least two complicated multicellular morphogenesis, which also species in the genus considering the differences of their forms the primary basis for myxobacterial taxonomy fruiting body colors. [7, 10]. Phylogenetically, the Myxobacterales are located In 1992, Shimkets and Woese [12] phylogenetically in the δ-division of Proteobacteria depending on the analyzed 12 representative strains from 10 myxobacteri- analysis of their 16S rDNA sequences [8, 14], but classi- al genera, including one cellulose-degrader.
    [Show full text]
  • Bacterial Type III Polyketide Synthases: Phylogenetic Analysis and Potential
    Arch Microbiol (2006) 185: 28–38 DOI 10.1007/s00203-005-0059-3 ORIGINAL PAPER Frank Gross Æ Nora Luniak Æ Olena Perlova Nikolaos Gaitatzis Æ Holger Jenke-Kodama Klaus Gerth Æ Daniela Gottschalk Æ Elke Dittmann Rolf Mu¨ller Bacterial type III polyketide synthases: phylogenetic analysis and potential for the production of novel secondary metabolites by heterologous expression in pseudomonads Received: 8 August 2005 / Revised: 7 October 2005 / Accepted: 10 November 2005 / Published online: 5 January 2006 Ó Springer-Verlag 2006 Abstract Type III polyketide synthases (PKS) were after the heterologous expression in Escherichia coli regarded as typical for plant secondary metabolism failed. Cultures of recombinant Pseudomonas sp. har- before they were found in microorganisms recently. Due bouring SoceCHS1 turned red upon incubation and the to microbial genome sequencing efforts, more and more diffusible pigment formed was identified as 2,5,7-trihy- type III PKS are found, most of which of unknown droxy-1,4-naphthoquinone, the autooxidation product function. In this manuscript, we report a comprehensive of 1,3,6,8-tetrahydroxynaphthalene. The successful het- analysis of the phylogeny of bacterial type III PKS and erologous production of a secondary metabolite using a report the expression of a type III PKS from the gene not expressed under administered laboratory con- myxobacterium Sorangium cellulosum in pseudomonads. ditions provides evidence for the usefulness of our ap- There is no precedent of a secondary metabolite that proach to activate such secondary metabolite genes for might be biosynthetically correlated to a type III PKS the production of novel metabolites. from any myxobacterium.
    [Show full text]
  • Investigation of the Central Carbon Metabolism of Sorangium Cellulosum: Metabolic Network Reconstruction and Quantification of Pathway Fluxes
    J. Microbiol. Biotechnol. (2009), 19(1), 23–36 doi: 10.4014/jmb.0803.213 First published online 23 October 2008 Investigation of the Central Carbon Metabolism of Sorangium cellulosum: Metabolic Network Reconstruction and Quantification of Pathway Fluxes Bolten, Christoph J.1, Elmar Heinzle1, Rolf Müller2, and Christoph Wittmann1,†* 1Biochemical Engineering, Saarland University, D-66041 Saarbrücken, Germany 2Pharmaceutical Biotechnology, Saarland University, D-66041 Saarbrücken, Germany Received: March 18, 2008 / Accepted: June 13, 2008 In the present work, the metabolic network of primary Keywords: Myxobacteria, primary metabolism, flux, NADPH, metabolism of the slow-growing myxobacterium Sorangium maintenance cellulosum was reconstructed from the annotated genome sequence of the type strain So ce56. During growth on glucose as the carbon source and asparagine as the nitrogen Myxobacteria have remarkable properties such the ability -1 source, So ce56 showed a very low growth rate of 0.23 d , to glide on solid surface, form fruiting bodies and biofilms, equivalent to a doubling time of 3 days. Based on a and live as micropredators [13]. Additionally, they exhibit complete stoichiometric and isotopomer model of the an outstanding biotechnological potential as sources for 13 central metabolism, C metabolic flux analysis was carried the production of natural compounds [13, 30, 31]. One of out for growth with glucose as carbon and asparagine as the most relevant species in the taxon of myxobacteria is nitrogen sources. Normalized to the uptake flux for glucose Sorangium cellulosum. Screening of various myxobacterial (100%), cells recruited glycolysis (51%) and the pentose species revealed that almost 50% of all newly discovered phosphate pathway (48%) as major catabolic pathways.
    [Show full text]
  • Diversity of Myxobacteria—We Only See the Tip of the Iceberg
    microorganisms Review Diversity of Myxobacteria—We Only See the Tip of the Iceberg Kathrin I. Mohr Microbial Drugs (MWIS), Helmholtz Centre for Infection Research (HZI), 38124 Braunschweig, Germany; [email protected]; Tel.: +49-531-6181-4251 Received: 6 June 2018; Accepted: 8 August 2018; Published: 11 August 2018 Abstract: The discovery of new antibiotics is mandatory with regard to the increasing number of resistant pathogens. One approach is the search for new antibiotic producers in nature. Among actinomycetes, Bacillus species, and fungi, myxobacteria have been a rich source for bioactive secondary metabolites for decades. To date, about 600 substances could be described, many of them with antibacterial, antifungal, or cytostatic activity. But, recent cultivation-independent studies on marine, terrestrial, or uncommon habitats unequivocally demonstrate that the number of uncultured myxobacteria is much higher than would be expected from the number of cultivated strains. Although several highly promising myxobacterial taxa have been identified recently, this so-called Great Plate Count Anomaly must be overcome to get broader access to new secondary metabolite producers. In the last years it turned out that especially new species, genera, and families of myxobacteria are promising sources for new bioactive metabolites. Therefore, the cultivation of the hitherto uncultivable ones is our biggest challenge. Keywords: myxobacteria; diversity; uncultured; secondary metabolites; new antibiotics 1. Introduction We know little about the real diversity of myxobacteria in the environment. How many myxobacteria are cultivable under standard laboratory conditions? How many resist these cultivation efforts and lie undiscovered in the ground? After an introduction to myxobacteria, the status of antibiotics, myxobacterial secondary metabolites, the Great Plate Count Anomaly phenomenon, and microbial biogeography, the diversity of cultivable and uncultivated myxobacteria in different habitats is presented.
    [Show full text]